Evidence map›Paper›PMID 37326951›Full record

ArticleJournal of nephrology2023

Clinical efficacy of the fourth dose of the BNT162b2 vaccine in maintenance dialysis patients.

Keren Cohen-Hagai, Tzipi Hornik-Lurie, Sydney Benchetrit, Naomi Nacasch, Ayelet Grupper, Yael Einbinder, Ori Wand, Moshe Shashar

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Keren Cohen-HagaiDepartment of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel.
Tzipi Hornik-LurieData Research Department, Meir Medical Center, Kfar Saba, Israel.
Sydney BenchetritDepartment of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel.
Naomi NacaschDepartment of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel.
Ayelet GrupperSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yael EinbinderDepartment of Nephrology and Hypertension, Meir Medical Center, Kfar Saba, Israel.
Ori WandDepartment of Pulmonology, Barzilai University Medical Center, Ashkelon, Israel.
Moshe ShasharDepartment of Nephrology and Hypertension, Laniado Hospital, Netanya, Israel. mshashar@laniado.org.il.ORCID http://orcid.org/0000-0002-9744-856X
Tel Aviv University · ILBen-Gurion University of the Negev · ILBoston University · USMeir Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesHighly effective vaccines against severe acute respiratory syndrome virus 2 have been developed and administered worldwide. However, protection from coronavirus disease 2019 is not absolute and an optimal vaccination regimen needs to be established. This study assessed the clinical efficacy of the coronavirus disease 2019 vaccine among dialysis patients receiving 3 or 4 doses of vaccine. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: This retrospective study was conducted using the electronic database of Clalit Health Maintenance Organization in Israel. Chronic dialysis patients treated with either hemodialysis or peritoneal dialysis during the coronavirus disease 2019 pandemic were included. We compared clinical outcomes of patients who had received three or four doses of the severe acute respiratory syndrome virus 2 vaccine.

resultsThis study included 1,030 patients on chronic dialysis, with a mean age of 68 ± 13 years. Among them, 502 patients had received 3 doses of the vaccine and 528 received 4 doses. Severe acute respiratory syndrome virus 2 infection rates, severe COVID-19 that resulted in hospitalizations, COVID-19-related mortality and all-cause mortality rates were lower among chronic dialysis patients who received a fourth dose of vaccine as compared to those who received only 3 doses (after controlling for age, sex and comorbidities). Despite lower mortality rates observed with the Omicron variant, the fourth dose was significantly associated with reduced COVID-19-related mortality (1.7% vs. 3.8%, p = 0.04). Odds ratio for COVID-19-related mortality was 0.44 with 95% CI 0.2-0.98.

conclusionsAs seen in the general population and with previous vaccine boosters, the fourth dose of the BNT162b2 vaccine reduced rates of severe COVID-19-related hospitalization and mortality among chronic dialysis patients. Further studies are needed to establish the optimal regimens of vaccination for patients on chronic dialysis.

Indexed as

COVID-19AgedAged, 80 and overBNT162 VaccineCOVID-19 VaccinesHumansMiddle AgedRenal DialysisRetrospective StudiesSARS-CoV-2Treatment OutcomeVaccinesBNT162 VaccineCOVID-19 VaccinesVaccinesAll-cause mortalityBreakthrough SARS-CoV-2 infectionsCOVID-19COVID-19–related mortalityKidney dialysis

Identifiers

PMID37326951
OpenAlexW4380872573

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.